Situation: A leading international life sciences company had to explain in court why its settlement of patent litigation with a potential generic entrant was driven by legitimate business considerations.
CRA contribution: CRA assembled a team with expertise in the pharmaceuticals industry, antitrust analysis, and game theory. Our economic analysis of the settlement accounted for the business risks facing the parties as well as the potential for a delay in generic entry.
Result: CRA’s expert analysis supported the defendant’s pre-trial motions, which were successful in having the case dismissed.
A look at Chinese courts’ new approach to IP damages
In this Law360 article, Fei Deng, Hong Qiao, and Yi Cheng examine the trend of Chinese courts toward awarding larger non-statutory damage awards in IP cases....